Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zahn

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Journal of Virology|September 16, 2016
Magnitude and Quality of Cytokine and Chemokine Storm during Acute Infection Distinguish Nonprogressive and Progressive Simian Immunodeficiency Virus Infections of Nonhuman PrimatesSheila M Keating, John W Heitman, Shiquan Wu, et al.
Nature Communications|April 7, 2023
Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaquesLaura Solforosi, Lea M M Costes, Jeroen T B M Tolboom, et al.
Annals of Internal Medicine|February 15, 2021
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus VaccineNadine C Salisch, Kathryn E Stephenson, Kristi Williams, et al.
NPJ Vaccines|October 21, 2020
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responsesRinke Bos, Lucy Rutten, Joan E M van der Lubbe, et al.
Nature|December 14, 2023
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaquesKatherine McMahan, Frank Wegmann, Malika Aid, et al.
The Lancet. HIV|February 21, 2020
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)Kathryn E Stephenson, Frank Wegmann, Frank Tomaka, et al.
NPJ Vaccines|March 20, 2021
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory diseaseJoan E M van der Lubbe, Sietske K Rosendahl Huber, Aneesh Vijayan, et al.
NPJ Vaccines|January 11, 2022
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamstersLisa H Tostanoski, Abishek Chandrashekar, Shivani Patel, et al.
The Journal of Experimental Medicine|April 28, 2021
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHPLaura Solforosi, Harmjan Kuipers, Mandy Jongeneelen, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Journal of Virology|September 16, 2016
Magnitude and Quality of Cytokine and Chemokine Storm during Acute Infection Distinguish Nonprogressive and Progressive Simian Immunodeficiency Virus Infections of Nonhuman PrimatesSheila M Keating, John W Heitman, Shiquan Wu, et al.
Nature Communications|April 7, 2023
Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaquesLaura Solforosi, Lea M M Costes, Jeroen T B M Tolboom, et al.
Annals of Internal Medicine|February 15, 2021
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus VaccineNadine C Salisch, Kathryn E Stephenson, Kristi Williams, et al.
NPJ Vaccines|October 21, 2020
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responsesRinke Bos, Lucy Rutten, Joan E M van der Lubbe, et al.
Nature|December 14, 2023
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaquesKatherine McMahan, Frank Wegmann, Malika Aid, et al.
The Lancet. HIV|February 21, 2020
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)Kathryn E Stephenson, Frank Wegmann, Frank Tomaka, et al.
NPJ Vaccines|March 20, 2021
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory diseaseJoan E M van der Lubbe, Sietske K Rosendahl Huber, Aneesh Vijayan, et al.
NPJ Vaccines|January 11, 2022
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamstersLisa H Tostanoski, Abishek Chandrashekar, Shivani Patel, et al.
The Journal of Experimental Medicine|April 28, 2021
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHPLaura Solforosi, Harmjan Kuipers, Mandy Jongeneelen, et al.
Pageof 7